Can Broad Biomedical Knowledge be Contextualized into Scenario-Grounded Propositions?
Qingyuan Zeng, Ziyang Chen, Pengxiang Cai, Zixin Guan, Anglin Liu, Lang Qin, Xinyao Lai, Jintai Chen
Abstract
Biomedical discovery often requires connecting broad biomedical knowledge with specific experimental or clinical data. Background knowledge suggests relevant mechanisms but is usually too general to map directly onto dataset variables, while data-driven patterns can be dataset-specific and hard to interpret mechanistically. We study this missing link as knowledge contextualization: transforming broad biomedical knowledge into evidence-supported, scenario-grounded propositions that domain experts can inspect, replay, and validate. We propose SCENE, a bi-level multi-agent framework that treats knowledge contextualization as iterative search. The upper level converts broad knowledge into search directions and grounds them in the dataset schema. The lower level executes these directions through multi-objective optimization to identify concrete propositions that balance evidential strength and data support. Feedback between the two levels progressively refines the search. We evaluate SCENE in two settings: discovering patient subgroups with heterogeneous treatment benefits in clinical trial scenarios, and identifying context-specific biological responses in LINCS L1000 studies. In clinical trials, SCENE discovers specific, well-supported subgroups and outperforms existing baselines. In L1000 studies, SCENE identifies perturbational contexts with strong target-response matching and high positive rates. These results show that SCENE bridges broad knowledge and scenario-specific evidence, producing traceable, inspectable hypotheses for follow-up validation.
AI Impact Assessments
(1 models)Scientific Impact Assessment: "Can Broad Biomedical Knowledge be Contextualized into Scenario-Grounded Propositions?"
1. Core Contribution
The paper formulates knowledge contextualization as an explicit problem in biomedical discovery: converting broad biomedical knowledge (e.g., "metabolic dysregulation may modify treatment response") into concrete, data-grounded propositions that are inspectable and replayable. The proposed framework, SCENE, implements this via a bi-level multi-agent architecture where (1) an upper level translates prior knowledge into bounded search directions mapped to dataset schemas, and (2) a lower level executes multi-objective evolutionary search over candidate rules balancing evidential strength and data support. A closed feedback loop connects both levels.
The key conceptual novelty is the explicit framing of the knowledge-to-evidence gap as a search problem, rather than treating knowledge integration and data-driven discovery as separate steps. This is a genuine, if somewhat incremental, conceptual contribution. The idea that LLM-based agents can propose directions that are then grounded through evolutionary optimization with Pareto selection is architecturally interesting.
2. Methodological Rigor
Strengths in evaluation design: The paper demonstrates careful experimental methodology. The clinical benchmark uses 50 paired train/holdout splits with a strict best-1 rule commitment protocol—rules are frozen before holdout evaluation, preventing post-hoc selection. Split-lineage tracking, leakage prevention (excluding treatment/outcome variables from candidate features), and detailed reporting contracts are commendable. The ablation study on L1000 systematically removes components.
Concerns about rigor:
3. Potential Impact
Positive directions: The paper addresses a real practical gap in translational biomedicine—researchers routinely struggle to connect domain knowledge with specific datasets. If SCENE's approach scales, it could meaningfully accelerate hypothesis generation in clinical trial analysis and drug mechanism studies. The proposition-level outputs with provenance chains are more useful than black-box predictions.
Limitations on impact:
4. Timeliness & Relevance
The paper is timely in several respects. The explosion of LLM capabilities creates new opportunities for knowledge-grounded scientific discovery. The problem of connecting broad knowledge with specific datasets is genuinely important and underserved. Multi-agent LLM frameworks are a hot area, and applying them to structured biomedical discovery is a natural and relevant direction.
However, the field is moving rapidly. The specific LLM backends used (Qwen3.5-9B, GLM-4.5-Air, DeepSeek-V3.2) will likely be superseded quickly, and the framework's dependence on prompt engineering and role contracts may not age well.
5. Strengths & Limitations
Key Strengths:
Notable Weaknesses:
Additional Observations:
The paper's clarity suffers from over-engineering of terminology and notation. The extensive formal apparatus (scenario adapters, manifest contracts, role instruction contracts) reads more like software documentation than a research contribution. While thoroughness is appreciated, the core algorithmic insight—iterative LLM-guided evolutionary search with Pareto selection—could be communicated more concisely.
The 100% direction consistency score for SCENE (Table 1, D-Cons.) is suspiciously perfect and warrants scrutiny—it may reflect the system's tendency to produce conservative, well-supported rules rather than genuinely novel subgroups.
Generated May 27, 2026
Comparison History (27)
Paper 1 introduces SCENE, a novel bi-level multi-agent framework addressing a fundamental challenge in biomedical discovery—bridging broad knowledge with scenario-specific evidence. It has broad applications across clinical trials and biological studies, with demonstrated utility in heterogeneous treatment effect discovery and perturbational biology. Paper 2, while methodologically rigorous and important for the LLM evaluation community, is primarily a critique/re-evaluation of a single benchmark with narrower scope. Paper 1's potential to enable new biomedical discoveries and its methodological novelty give it higher long-term impact.
Paper 1 addresses a fundamental bottleneck in AI: the reliance on human-curated data and external verifiers for LLM training. By enabling self-evolving LLMs to reliably use intrinsic confidence to mitigate noisy self-feedback, it offers a scalable solution to the AI 'data wall' problem. This methodological innovation has broad, domain-agnostic impact across all fields utilizing generative AI. While Paper 2 presents a strong, applied framework for biomedical discovery, Paper 1's foundational contribution to autonomous AI capability development gives it a wider and more immediate transformational impact across the broader scientific landscape.
Paper 1 addresses a fundamental challenge in biomedical discovery—bridging broad knowledge with scenario-specific data—with a novel framework (SCENE) validated across clinical trials and biological studies. Its real-world applications in precision medicine and drug discovery are immediately impactful. Paper 2 contributes to LLM spatial reasoning with a technically interesting MCTS-guided approach, but operates in a more incremental space of LLM capability improvement. Paper 1's methodological contribution (knowledge contextualization as iterative search) opens a new research direction with broader interdisciplinary impact across biomedicine.
Paper 1 introduces a novel, broadly applicable framework (SCENE) for contextualizing general biomedical knowledge into dataset-grounded, inspectable propositions, validated across clinical trials and LINCS L1000—high real-world translational potential and cross-domain relevance (biomedicine, ML, causal/hypothesis generation). Its methodological contribution is a concrete bi-level multi-agent search/optimization pipeline with measurable gains over baselines. Paper 2 provides valuable mechanistic insights and training heuristics for RLVR in LLMs, but its impact is narrower (specific to RLVR setups) and more incremental relative to fast-moving alignment literature. Overall, Paper 1 likely yields wider and more durable scientific impact.
Paper 1 addresses a critical, timely issue in AI safety: emergent social biases in autonomous LLM agents. Its findings on how in-group biases compound into structural inequality have broad, interdisciplinary implications across computer science, sociology, and tech policy, impacting how multi-agent networks are audited and regulated. While Paper 2 offers a valuable methodological advancement for biomedical discovery, Paper 1's insights into fundamental AI behavior and alignment give it a wider breadth of impact and higher potential to shape the rapidly growing field of AI agent deployment.
Paper 2 addresses a fundamental challenge in biomedical discovery—bridging broad knowledge with scenario-specific data—with broad applicability across clinical trials, drug discovery, and biological research. Its multi-agent framework for knowledge contextualization is highly novel and addresses a widely recognized gap. Paper 1, while achieving state-of-the-art results in VSR with an innovative diffusion-based approach, addresses a narrower technical problem. Paper 2's potential to accelerate biomedical hypothesis generation and validation gives it broader cross-disciplinary impact and greater real-world significance.
Paper 2 has higher estimated impact due to strong novelty and timeliness in mechanistic interpretability and LLM safety: it shows refusal is linearly decodable from intermediate activations and exploits this signal to speed jailbreak prompt search via probe-guided optimization. The method is broadly applicable across models and directly informs both attack and defense research, with cross-field relevance (security, interpretability, alignment). Paper 1 is valuable for biomedical hypothesis generation, but impact may be more domain-specific and dependent on downstream validation and dataset/schema integration details.
Paper 2 likely has higher impact: it identifies a broadly relevant failure mode (action-grammar destruction) in agent context compression, proposes a practical, inference-free solution with strong empirical validation across many environments/backbones, and offers immediate applicability to scalable LLM-agent deployment (cost/latency reduction). Its methodological rigor (multi-cell evaluation, ablations, clear diagnosis→design linkage) and cross-field breadth (agents, systems, RL, prompt engineering) are high and timely given rapid growth of agentic LLMs. Paper 1 is valuable but more domain-specific to biomedicine and multi-agent hypothesis generation.
Paper 2 addresses a fundamental challenge in biomedical discovery—bridging broad knowledge with specific experimental data—with a novel multi-agent framework (SCENE) applicable across clinical trials and biological studies. Its potential for real-world impact in drug discovery, precision medicine, and biological research is substantial, spanning multiple biomedical fields. Paper 1, while methodologically rigorous and practically useful, addresses a more niche optimization problem in process mining conformance checking with incremental improvements over existing A* methods, limiting its broader scientific impact.
Paper 1 likely has higher impact: it introduces a novel, general framework (SCENE) for contextualizing broad biomedical knowledge into dataset-grounded, inspectable hypotheses, addressing a widely recognized bottleneck in biomedical discovery and translational research. It demonstrates real-world applicability across two important domains (clinical trial subgroup discovery and LINCS L1000 perturbation analysis) and emphasizes traceability/validation, increasing adoption potential. Paper 2 provides valuable insights into PPO failure modes in cumulative-damage long-horizon tasks, but its scope is narrower and demonstrated on stylized calibrated environments, limiting breadth and immediate real-world uptake.
Paper 2 (SCENE) addresses a fundamental challenge in biomedical discovery—bridging broad knowledge with specific experimental data—with a novel multi-agent framework that has immediate practical applications in clinical trials and drug discovery. It demonstrates concrete utility across multiple biomedical settings. While Paper 1 provides valuable methodological insights about evaluating LLM compositional reasoning (composition collapse), its impact is more narrowly focused on AI evaluation methodology. Paper 2's breadth of real-world biomedical applications, combined with its novel framework for knowledge contextualization, gives it higher potential for cross-disciplinary impact.
Paper 2 addresses a fundamental challenge in biomedical discovery by linking broad knowledge to specific experimental or clinical data. Its framework can be applied across numerous high-impact areas, such as clinical trials and systems biology, giving it much broader scientific relevance and potential application. While Paper 1 presents a rigorous and practical solution, its focus on steel-industry VOCs is highly domain-specific, likely limiting its overall scientific impact and citation potential compared to the broader biomedical scope of Paper 2.
Paper 2 has higher estimated impact due to a clearer novel problem formulation (knowledge contextualization), a concrete algorithmic contribution (SCENE bi-level multi-agent iterative search with multi-objective optimization), and stronger methodological rigor via evaluations on high-value biomedical tasks with baselines and measurable improvements. Its applications (clinical trial subgroup discovery, context-specific biological responses) are directly actionable and timely for precision medicine, and the “traceable, inspectable hypotheses” angle supports real-world adoption. Paper 1 is promising systems work, but appears more engineering-focused with less formal validation and narrower, tool-centric impact.
Paper 1 presents a highly innovative integration of a multimodal foundation model with a tool-augmented agent for polymer discovery. By bridging fragmented chemical representations and enabling property-conditioned inverse design grounded in literature, it offers a direct, end-to-end solution for a major bottleneck in materials science. Its potential to physically generate novel materials for real-world applications (energy, biomedicine) gives it a broader and more tangible scientific impact compared to the methodological knowledge-contextualization framework proposed in Paper 2.
Paper 2 (SCENE) addresses a fundamental challenge in biomedical discovery—bridging broad knowledge with scenario-specific data—through a novel multi-agent framework with broader applicability across clinical trials and biological studies. It offers stronger methodological innovation (bi-level multi-agent optimization), demonstrates impact across multiple domains, and tackles a more generalizable problem. Paper 1 contributes a useful speech dataset for medical AI but is more incremental, focused on a narrower application (medical dialogue), and its LLM benchmarking findings (overconfidence) are relatively unsurprising.
Paper 2 addresses a broadly relevant problem—bridging general biomedical knowledge with scenario-specific data—with a novel multi-agent framework (SCENE) applicable to clinical trials and biological studies. Its potential for real-world biomedical impact, interdisciplinary relevance (AI + biomedicine), and timeliness (leveraging LLM-based agents for scientific discovery) give it broader impact potential. Paper 1 makes solid theoretical and practical contributions to ASP(Q) complexity and implementation, but targets a narrower computational logic audience with more incremental advances in a specialized formalism.
Paper 1 exposes a critical structural vulnerability in RLHF, the dominant alignment method for large language models. Given the widespread deployment of LLMs across virtually all domains, identifying and addressing fundamental flaws in their safety alignment has massive, immediate implications for the entire AI community and broader society. Paper 2 is highly valuable for biomedical discovery, but Paper 1's focus on AI safety and alignment tampering offers a broader and more urgent scientific impact.
Paper 2 has higher estimated impact due to broader applicability and timeliness: improving RAG for semi-structured corpora is a widely shared bottleneck across e-commerce, enterprise search, and technical QA. It contributes both a method (DualGraph combining semantic retrieval with symbolic querying) and a new benchmark (SpecsQA), which can catalyze follow-on work and standardize evaluation. Methodologically, the dual-view design and comparisons across diverse baselines suggest solid rigor. Paper 1 is novel and valuable for biomedical hypothesis contextualization, but its impact is more domain-specific and may generalize less broadly.
Paper 2 addresses a fundamental challenge in biomedical discovery—bridging broad knowledge with specific experimental data—through a novel multi-agent framework (SCENE) with rigorous evaluation across clinical trials and biological studies. It has clear real-world applications in precision medicine and drug discovery, methodological rigor with multiple evaluation settings, and broad potential impact across biomedicine. Paper 1 proposes a conceptual framework for agentic AI technical debt that, while timely, is more of a management/measurement tool with limited empirical validation (spreadsheet simulation) and narrower applicability.
Paper 2 likely has higher impact due to strong timeliness and broad relevance: it addresses safety failures in widely deployed multimodal LLMs, proposes an automated black-box attack/measurement framework, and introduces a benchmark across diverse threat scenarios. Its findings (high ASR across major models) are immediately actionable for alignment, evaluation, and policy, with cross-field implications spanning ML security, HCI safety, and AI governance. Paper 1 is novel and valuable for biomedical hypothesis generation, but its impact is more domain-specific and may face higher barriers to real-world adoption and validation.